-
1دورية أكاديمية
المؤلفون: Kelly, Karen, Altorki, Nasser K, Eberhardt, Wilfried EE, O'Brien, Mary ER, Spigel, David R, Crinò, Lucio, Tsai, Chun-Ming, Kim, Joo-Hang, Cho, Eun Kyung, Hoffman, Philip C, Orlov, Sergey V, Serwatowski, Piotr, Wang, Jiuzhou, Foley, Margaret A, Horan, Julie D, Shepherd, Frances A
المصدر: Journal of Clinical Oncology. 33(34)
مصطلحات موضوعية: Cancer, Lung Cancer, Prevention, Clinical Trials and Supportive Activities, Lung, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Double-Blind Method, ErbB Receptors, Erlotinib Hydrochloride, Female, Follow-Up Studies, Humans, International Agencies, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Survival Rate, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/2nv2v0wkTest
-
2دورية أكاديمية
المؤلفون: Kobat, Hasan, Elkonaissi, Islam, Foreman, Emma, O'Brien, Mary, Dorak, Mehmet Tevfik, Nabhani-Gebara, Shereen
المصدر: Journal of Oncology Pharmacy Practice; Apr2023, Vol. 29 Issue 3, p646-662, 17p
مصطلحات موضوعية: CARDIOTOXICITY, LUNG cancer, DRUG efficacy, IMMUNE checkpoint inhibitors, EPIDERMAL growth factor receptors, ANTINEOPLASTIC agents, RETROSPECTIVE studies, CARDIOVASCULAR diseases, ACQUISITION of data, PROTEIN-tyrosine kinase inhibitors, ELECTROCARDIOGRAPHY, MEDICAL records, COMORBIDITY, PHARMACODYNAMICS
-
3دورية أكاديمية
المؤلفون: Kumar, Rajiv, Lu, Shir, Minchom, Anna, Sharp, Adam, Davidson, Michael, Gunapala, Ranga, Yap, Timothy, Bhosle, Jaishree, Popat, Sanjay, O'Brien, Mary, Lu, Shir Kiong, Yap, Timothy A, O'Brien, Mary E R
المصدر: Cancer Chemotherapy & Pharmacology; Feb2016, Vol. 77 Issue 2, p375-383, 9p
مصطلحات موضوعية: CANCER treatment, NON-small-cell lung carcinoma, ERLOTINIB, CANCER patients, THYMIDYLATE synthase, DRUG resistance in cancer cells, DRUG dosage, COMBINATION drug therapy, THERAPEUTICS, ANTINEOPLASTIC agents, CLINICAL trials, DRUG administration, DOSE-effect relationship in pharmacology, EPIDERMAL growth factor, LUNG cancer, LUNG tumors, GENETIC mutation, PROGNOSIS, TUMOR classification, TREATMENT effectiveness
-
4دورية أكاديمية
المؤلفون: O'Brien, Mary E.R., Socinski, Mark A., Popovich, Alexander Y., Bondarenko, Igor N., Tomova, Antoaneta, Bilynsky˘ı, Borys T., Hotko, Yevhen S., Ganul, Valentin L., Kostinsky, Ippolit Y., Eisenfeld, Amy J., Sandalic, Larissa, Oldham, Fred B., Bandstra, Bruce, Sandler, Alan B., Singer, Jack W.
المصدر: Journal of Thoracic Oncology, 3(7)
مصطلحات موضوعية: Deoxycytidine, Carcinoma, Non-Small-Cell Lung, Survival Rate, Female, Humans, Paclitaxel, Lung Neoplasms, Male, Polyglutamic Acid, Middle Aged, Antineoplastic Agents, Phytogenic, Antimetabolites, Antineoplastic
العلاقة: https://doi.org/10.17615/ygtf-rq83Test; https://cdr.lib.unc.edu/downloads/xg94hz232?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/xg94hz232Test
الإتاحة: https://doi.org/10.17615/ygtf-rq83Test
https://cdr.lib.unc.edu/downloads/xg94hz232?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/xg94hz232Test -
5دورية أكاديمية
المؤلفون: O’Brien, Mary E.R.1 mary.obrien@rmh.nhs.uk, Gaafar, Rabab2 rabab.gaafar@gmail.com, Hasan, Baktiar3 Baktiar.hasan@eortc.be, Menis, Jessica3 Jessica.menis@eortc.be, Cufer, Tanja4 tanja.cufer@klinika-golnik.si, Popat, Sanjay1 sanjay.popat@rmh.nhs.uk, Woll, Penella J.5 p.j.woll@sheffield.ac.uk, Surmont, Veerle6 veerle.surmont@uzgent.be, Georgoulias, Vassilis7 georgsec@med.uoc.gr, Montes, Ana8 ana.montes@gstt.nhs.uk, Blackhall, Fiona9 Fiona.Blackhall@christie.nhs.uk, Hennig, Ivo10 ivo.hennig@nuh.nhs.uk, Schmid-Bindert, Gerald11 gerald.schmid-bindert@umm.de, Baas, Paul12 p.baas@nki.nl
المصدر: European Journal of Cancer. Aug2015, Vol. 51 Issue 12, p1511-1528. 18p.
مصطلحات موضوعية: *ANTINEOPLASTIC agents, *CONFIDENCE intervals, *LUNG cancer, *PLACEBOS, *SAFETY, *SURVIVAL, *PROTEIN-tyrosine kinase inhibitors, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *BLIND experiment, *THERAPEUTICS
مصطلحات جغرافية: UNITED Kingdom
-
6دورية أكاديمية
المؤلفون: Walder, David1 david.walder@rmh.nhs.uk, O'Brien, Mary1 mary.o'brien@rmh.nhs.uk
المصدر: European Journal of Cancer. Apr2017, Vol. 75, p192-194. 3p.
مصطلحات موضوعية: *ANTINEOPLASTIC agents, *LUNG cancer treatment, *CHRONIC diseases, *PROGNOSIS, *SURVIVAL, *TREATMENT effectiveness, *PROTEIN kinase inhibitors
-
7دورية أكاديمية
المؤلفون: O’Brien, Mary E.R.1 mary.obrien@rmh.nhs.uk, Gaafar, Rabab M.2, Popat, Sanjay1, Grossi, Francesco3, Price, Allan4, Talbot, Denis C.5, Cufer, Tanja6, Ottensmeier, Christian7, Danson, Sarah8, Pallis, Athanasios9, Hasan, Baktiar9, Van Meerbeeck, Jan P.10, Baas, Paul11
المصدر: European Journal of Cancer. Sep2013, Vol. 49 Issue 13, p2815-2822. 8p.
مصطلحات موضوعية: *CISPLATIN, *ANTINEOPLASTIC agents, *CONFIDENCE intervals, *LONGITUDINAL method, *MESOTHELIOMA, *SURVIVAL, *DESCRIPTIVE statistics
-
8دورية أكاديمية
المؤلفون: O’Brien, Mary E.R.1 mary.obrien@rmh.nhs.uk, Konopa, Krzystof2, Lorigan, Paul3, Bosquee, Lionel4, Marshall, Ernest5, Bustin, Frederique6, Margerit, Sabine7, Fink, Christian8, Stigt, Jos A.9, Dingemans, Anne Marie C.10, Hasan, Baktiar7, Van Meerbeeck, Jan11, Baas, Paul12
المصدر: European Journal of Cancer. Oct2011, Vol. 47 Issue 15, p2322-2330. 9p.
مصطلحات موضوعية: *ANTINEOPLASTIC agents, *CISPLATIN, *DRUG toxicity, *LUNG tumors, *STATISTICAL sampling, *DISEASE progression
-
9دورية أكاديمية
المؤلفون: O'Brien, Mary, Eckardt, John, Ramlau, Rodryg
المصدر: Oncologist; Oct2007, Vol. 12 Issue 10, p1194-1204, 11p, 3 Charts
مصطلحات موضوعية: ANTINEOPLASTIC agents, LUNG cancer, CANCER treatment, CAMPTOTHECIN, DNA topoisomerase I, SMALL cell lung cancer, CISPLATIN, COMBINATION drug therapy
-
10دورية أكاديمية
المؤلفون: Yau, Thomas, Swanton, Charles, Chua, Sue, Sue, Ashley, Walsh, Geraldine, Rostom, A., Johnston, Stephen, O'Brien, Mary, Smith, Ian
المصدر: Acta Oncologica; Mar2006, Vol. 45 Issue 2, p196-201, 6p, 2 Charts, 2 Graphs
مصطلحات موضوعية: BRAIN tumors, METASTASIS, CANCER invasiveness, BREAST cancer, TRASTUZUMAB, ANTINEOPLASTIC agents, CANCER treatment